Welcome to our dedicated page for HUTCHMED (China) SEC filings (Ticker: HMDCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HUTCHMED (China)'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HUTCHMED (China)'s regulatory disclosures and financial reporting.
HUTCHMED (China) Limited reports the vesting of non-performance based awards under its Long Term Incentive Plan. On March 13, 2026, awards granted on March 13, 2024 to Dr. Weiguo Su, Executive Director, Chief Executive Officer and Chief Scientific Officer, vested into 19,913 ordinary shares.
The vesting occurred at a price of nil and outside a trading venue, reflecting equity-based compensation rather than a market transaction. The notification is made in line with UK Market Abuse Regulation requirements and relates to ordinary shares of US$0.10 par value.
HUTCHMED (China) Ltd Chief Financial Officer Cheng Chig Fung filed an initial ownership report showing existing equity holdings, not new trades. He holds several share options over American depositary shares with exercise prices of $22.0900, $27.9400, $10.7500 and $12.5100, expiring between 2030 and 2033.
The filing also lists 1,463,698 ordinary shares and 56,693 American depositary shares held directly, plus 38,567 ordinary shares held indirectly through a Long Term Incentive Plan. Each American depositary share represents 5 ordinary shares, and plan awards are scheduled to vest in 2027 subject to vesting criteria.
HUTCHMED (China) Limited reported that long-term incentive awards granted on June 5, 2023 under its Long Term Incentive Plan have vested following the announcement of its 2025 annual results. On March 10, 2026, 524,079 ordinary shares vested to Dr Weiguo Su and 202,238 ordinary shares vested to Mr Johnny Cheng, totaling 726,317 shares.
These awards vested at nil price and relate to ordinary shares of US$0.10 each. Both executives are classified as persons discharging managerial responsibilities, and the transactions took place outside a trading venue, in line with UK Market Abuse Regulation notification requirements.
HUTCHMED (China) Ltd director Yang Ling filed an initial Form 3, formally reporting their beneficial ownership position as an insider of the company. The available data show no reported purchases, sales, acquisitions, or disposals of HUTCHMED securities in this filing.
HUTCHMED (China) Ltd director Daniel Shao Weng Tan filed an initial insider ownership report on Form 3. The filing lists him as a director of the company and does not report any insider buy, sell, acquisition, or disposition transactions at this time.
HUTCHMED (China) Ltd director Renu Bhatia has filed an initial Form 3 reporting her holdings in the company. The filing shows direct beneficial ownership of 16,000 ordinary shares following the reported position, with no specific buy or sell transaction indicated in this disclosure.
HUTCHMED (China) Ltd director Tony Shu Kam Mok filed an initial ownership report on Form 3. He reported beneficial ownership of 27,341 American depositary shares. Each American depositary share represents 5 ordinary shares of HUTCHMED.
HUTCHMED (China) Ltd director Wong Tak Wai has filed a Form 3, which is an initial statement of insider ownership. The filing lists him as a director but shows no share transactions and no reported buy, sell, acquire, or dispose activity at this time.
HUTCHMED (China) Ltd director Eldar Dan filed an initial ownership report listing his direct equity stake in the company. He reported holding 19,000 ordinary shares and 26,332 American depositary shares. A footnote states that each American depositary share represents 5 ordinary shares. The filing does not show any new buy or sell transactions, only existing holdings.
HUTCHMED (China) Ltd reported that Hu Chaohong is a director and a reporting person on a Form 3. The data provided shows no insider transactions, with zero shares listed as bought, sold, acquired, or disposed in this filing snapshot.